Zobrazeno 1 - 10
of 326
pro vyhledávání: '"59"'
Autor:
Jae-Sook Ahn, Ho-Sup Lee, Young Don Joo, Y.Y. Cho, Hyeoung-Joon Kim, Yoo Jin Lee, Ho Jin Shin, Sangmin Lee, Moo-Kon Song, Sung Hwa Bae, Yang Soo Kim, Won Sik Lee, Sang-Kyun Sohn, Joon Ho Moon, Hyung-Ryong Kim
Publikováno v:
Leukemia Research. 39:S29
Autor:
A. Roth, S. HsuSchmitz, Ralph A. Schmid, M. Pless, Anastase Spiliopoulos, Rolf A. Stahel, Hans B. Ris, Daniel C. Betticher, W. Weder, Thomas Cerny
Publikováno v:
Lung Cancer. 49:S14
Autor:
Fariba Fayaz, Khosro Agin
Publikováno v:
Lung Cancer. 41:S287
Publikováno v:
Cancer Chemotherapy and Pharmacology. 87:23-30
The ideal starting dose for an oncology first-in-patient (FIP) trial should be low enough to be safe but not too far removed from therapeutically relevant doses. A low starting dose combined with small dose increments could lead to a lengthy dose esc
Autor:
Eric J. Small, Christopher L. Corless, Tomasz M. Beer, Erik W. Foss, Kristine M. Eilers, Brooke Beckett, Julie N. Graff, Joshi J. Alumkal, Alexander R. Guimaraes, Alice Fung, Bryan R. Foster, Shawna Bailey, George Thomas, Jeremy Cetnar, Derrick Tao
Publikováno v:
JCO Precision Oncology. :1-11
Purpose Metastatic castration-resistant prostate cancer (CRPC) is the lethal form of the disease. Many groups have performed mutational or immunohistochemistry (IHC) testing in metastatic CRPC to identify treatment targets. However, the frequency wit
Autor:
Candice Johnstone, Kulwinder S. Dua, Mandana Kamgar, Abdul H. Khan, Paul Linsky, Sakti Chakrabarti, James P. Thomas, Aniko Szabo, Lauren Jurkowski, M.E. Shukla, David W. Johnstone, John J. Evans, Lindsay Puckett, Mario Gasparri, Ben George, Elizabeth Gore, Srivats Madhavan, Aditya Shreenivas
Publikováno v:
Journal of Clinical Oncology. 39:231-231
231 Background: Both peri-operative chemotherapy and neoadjuvant chemoradiation have been shown to improve outcomes in patients (pts) with LA-GEJ CA compared to surgery alone. Rates of post-operative chemotherapy delivery remain suboptimal. Total neo
Autor:
Vanesa García-Barberán, Isabel Díaz-Millán, Pedro Pérez-Segura, Santiago Cabezas-Camarero, Rebeca Pérez-Alfayate, María L. Gandía
Publikováno v:
Journal of Clinical Oncology. 38:69-69
69 Background: Plasma immune biomarkers such as soluble plasma PD-L1 (sPD-L1) may serve as surrogates of the immune condition of cancer patients and be potential markers of response to different immunotherapy modalities. Very few data exist regarding
Autor:
Erin Zagadailov, Paul J Bröckelmann, Brian Seal, Timothy M Illidge, Courtney Johnson, Viktor V. Chirikov, Shelby Corman, Cynthia Macahilig, Mehul Dalal
Publikováno v:
Zagadailov, E A, Corman, S, Chirikov, V, Johnson, C, Macahilig, C, Seal, B, Dalal, M R, Broeckelmann, P J & Illidge, T 2018, ' Real-world effectiveness of brentuximab vedotin versus physicians' choice chemotherapy in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplantation in the United Kingdom and Germany ', Leukemia and Lymphoma, vol. 59, no. 6, pp. 1413-1419 . https://doi.org/10.1080/10428194.2017.1382698
Zagadailov, E A, Corman, S, Chirikov, V, Johnson, C, Macahilig, C, Seal, B, Dalal, M R, Broeckelmann, P J & Illidge, T 2018, ' Real-world effectiveness of brentuximab vedotin versus physicians' choice chemotherapy in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplantation in the United Kingdom and Germany ' Leukemia & lymphoma, vol 59, no. 6, pp. 1413-1419 . DOI: 10.1080/10428194.2017.1382698
Zagadailov, E A, Corman, S, Chirikov, V, Johnson, C, Macahilig, C, Seal, B, Dalal, M R, Broeckelmann, P J & Illidge, T 2018, ' Real-world effectiveness of brentuximab vedotin versus physicians' choice chemotherapy in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplantation in the United Kingdom and Germany ' Leukemia & lymphoma, vol 59, no. 6, pp. 1413-1419 . DOI: 10.1080/10428194.2017.1382698
This retrospective study compared effectiveness of (brentuximab vedotin) BV to other chemotherapies in patients with rrHL following an autologous stem cell transplant (ASCT). Data originated from a medical chart review of patients treated in real-wor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aab0150e0b73ad51dc94323ad367f593
https://doi.org/10.1080/10428194.2017.1382698
https://doi.org/10.1080/10428194.2017.1382698
Publikováno v:
Oncology Letters. 10:2311-2318
In the present study, the cases of 59 children diagnosed with neuroblastoma (NB) were retrospectively analyzed to assess the association between the short-term efficacy of treatment and prognostic factors. In total, 59 patients with NB that were diag
Publikováno v:
Cancer Research. 78:P3-04
Background: TP53 and PIK3CA are the most frequently mutated genes in breast cancer. However, there is limited data evaluating the impact of somatic mutations in TP53 and/or PIK3CA patients (pts) with metastatic breast cancer (MBC) who have undergone